AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06525389
Drug: Flucytosine (5FC) placebo pill
RxNorm normalized name: flucytosine Pill
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
Trial: NCT06525389
Drug: Deoxycholate Amphotericin B (DAmB)
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
Trial: NCT04815148
Drug: MH004 Ia(0.1%)
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Trial: NCT04815148
Drug: MH004 Ia(0.3%)
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Trial: NCT04815148
Drug: MH004 Ia(1%)
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Trial: NCT04815148
Drug: MH004 Ia(3%)
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Trial: NCT05373615
Drug: Cefiderocol
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
Trial: NCT04520711
Drug: CDX-1140
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant fully human IgG2κ monoclonal antibody
Trial: NCT04520711
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized immunoglobulin G4 (IgG4) monoclonal antibody
Trial: NCT00239252
Drug: Interferon alfacon-1
RxNorm normalized name: interferon alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05351164
Drug: Metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
Trial: NCT00002317
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06078384
Drug: Pembrolizumab 25 mg/ml
RxNorm normalized name: pembrolizumab 25 MG/ML
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion.
Trial: NCT06078384
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injectable solution for IV administration. Dose of 80 mg/m² weekly.
Trial: NCT04793022
Drug: TIVA with Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol
Trial: NCT06178601
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
Trial: NCT06178601
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
Trial: NCT05504642
Drug: Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
Trial: NCT05507112
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
Trial: NCT06175949
Drug: HRS-7085 Tablets
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
Trial: NCT05649956
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg PO daily
Trial: NCT05190094
Drug: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
Trial: NCT00781482
Drug: eszopiclone, zolpidem, placebo
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
Trial: NCT04219046
Drug: Naloxégol oxalate
RxNorm normalized name: Naloxegol Oxalate
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration once daily
Trial: NCT06086340
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib with an aromatase inhibitor therapy
Trial: NCT06462105
Drug: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
Trial: NCT04716296
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be given for the second stage of the DBS surgery.
Trial: NCT04716296
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be given for the second stage of the DBS surgery.
Trial: NCT04927169
Drug: Interleukin-7
RxNorm normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Trial: NCT05819866
Drug: Leriglitazone
RxNorm normalized name: Leriglitazone
DrugBank: Leriglitazone (DB15021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
Trial: NCT04495608
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period).
Trial: NCT05216354
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
Trial: NCT06048484
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg intravenously (IV)
Trial: NCT06048484
Drug: Quemliclustat
RxNorm normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IV
Trial: NCT06048484
Drug: Etrumadenant
RxNorm normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg orally
Trial: NCT06208371
Drug: Palliative Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
Trial: NCT05373914
Drug: Cudetaxestat (BLD-0409)
RxNorm normalized name: Cudetaxestat
DrugBank: Cudetaxestat (DB18203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cudetaxestat - 250mg tablets (orally)
Trial: NCT06451198
Drug: Indobufen
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
Trial: NCT06451198
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
Trial: NCT06451198
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
Trial: NCT04871919
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablets are administered in accordance with the product label
Trial: NCT06522828
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT06522828
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy
Trial: NCT05538663
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
Trial: NCT05538663
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
Trial: NCT06155396
Drug: Disitamab Vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg IV every 2 weeks
Trial: NCT06155396
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg IV every 2 weeks
Trial: NCT06220942
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pregnant female presented for C.S. after receiving spinal anesthesia, recording the vital data, phenylephrine will be given in a dose of 50 µg IV immediately if the heart rate increases ≥ 20 % of baseline
Trial: NCT06017362
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical insulin 1UI/ml 4 times a day
Trial: NCT06017362
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artificial tears 4 times a day
Trial: NCT00000991
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000991
Drug: Sulfamethoxazole-Trimethoprim
RxNorm normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000991
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000991
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05889052
Drug: Sulfadoxine pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Trial: NCT04755088
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to receive Surufatinib 300mg on Day 1
Trial: NCT05549752
Drug: Flecainide Injectable Solution
RxNorm normalized name: flecainide Injectable Solution
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
Trial: NCT05549752
Drug: Amiodarone Injectable Solution
RxNorm normalized name: amiodarone Injectable Solution
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
Trial: NCT04595682
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
Trial: NCT04954820
Drug: Lutathera
RxNorm normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 additional infusions of Lutathera®
Trial: NCT05150899
Drug: Tamsulosin Hcl 0.4Mg Cap
RxNorm normalized name: TAMSULOSIN HCL 0.4MG CAP
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alpha blocker
Trial: NCT05150899
Drug: fexofenadine 180 mg Oral tablet
RxNorm normalized name: fexofenadine 180 mg oral tablet
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antihistaminic
Trial: NCT04712058
Drug: Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]
RxNorm normalized name: bictegravir / emtricitabine / tenofovir alafenamide Oral Tablet [Biktarvy]
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
Trial: NCT06378112
Drug: GTO®
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
Trial: NCT04283513
Drug: Virazole
RxNorm normalized name: Virazole
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
Trial: NCT06145308
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (HER2 expression group) : Vedicetumab (2.5mg/kg, Q2w) alone or combined with platinum-based chemotherapy drugs (carboplatin 200-250mg/m2, Q2w or cisplatin 50mg/m2, Q2w) Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (HER2 expression group) : Vedicetumab monotherapy (2mg/kg, IV, Q2w) or vedicetumab (2mg/kg, IV, Q2w) combined with immune checkpoint inhibitors (triprilizumab 3mg/kg, IV, Q2w, etc.) or vedicetumab (2mg/kg, IV, Q2W, etc.) Q2w) in combination with oral HER2 TKI (pyrrotinib 400mg po qd and other drugs) or Vedicetsol in combination with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w).
Trial: NCT06145308
Drug: albumin paclitaxel with platinum
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w, ; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w,
Trial: NCT05480111
Drug: Local anesthesia at incision site
RxNorm normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.25% Bupivacaine will be given at incision site
Trial: NCT05480111
Drug: Sham QL
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
Trial: NCT05480111
Drug: QL
RxNorm normalized name: Qlosi
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
Trial: NCT05891795
Drug: Clascoterone 1% Top Cream
RxNorm normalized name: CLASCOTERONE 1% TOP CREAM
DrugBank: Clascoterone (DB12499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply a thin layer to the affected area twice daily.
Trial: NCT04966663
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antineoplastic agent
Trial: NCT04966663
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antineoplastic agent
Trial: NCT04966663
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antineoplastic agent
Trial: NCT04966663
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antineoplastic agent
Trial: NCT04966663
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antineoplastic agent